Express Pharma December 2017

CPhI & P-MEC INDIA 2017 SPECIAL

the concepts of reverse inno- data as depicted in the table in Acquity QDa along with its ease quantification, unknown
vation we procured multiple Figure-1. of use, makes this detector a real peak identifications and
formulations of API called as universal detector for most of OOS/OOT studies.
'Metoclopramide. Metoclo- A representative image of the pharma applications and a
pramide is used to prevent how PDA-Acquity QDa gives must investment for R&D and Acquity QDa is a tool for
nausea and vomiting. the spectra and mass no. si- QC labs conducting orthogonal peak
multaneously on Empower purity studies, wherein homo-
The samples used in case Software is shown in Figure- observed formulation-specific fast screening tool in R&D's geneity of the peak can be ver-
study were Metoclopramide 2. This data clearly reflects impurities/excipient peaks to compare analytical sam- ified or confirmed by selecting
HCl 10mg Tablets from two the advantage of an easy to and they were identified by ples like multiple source of the purity tab from Empower
different brands (Brand X use mass detector Acquity their mass number. API's, different grades of Software. Here, we get mass
and Y) and Metoclopramide QDa. Based on the data gener- API, API versus formulation number at start, apex and end
HCl injection 5mg/ml from ated using Acquity QDa de- Hence to conclude, Ac- and stressed samples versus of the peak. This unique fea-
Brand Y. tector coupled with PDA de- quity QDa is going to be unstressed samples. It is use- ture of Acquity QDa along
tector, it was found that USP 'must to have' detector for all ful in QC labs w.r.t cleaning with its ease of use, makes
All the samples were pre- specified impurity, 4-Amino- R&Ds and QC labs working sample analysis/validations, this detector a real universal
pared in a uniform way and 5-chloro-N-(2-(diethylamino) on generics, complex gener- low level genotoxic impurity detector for most of the
were run under identical con- ethyl)-2-hydroxybenzamide ics, nutraceuticals etc. It's a pharma applications and a
ditions using liquid chro- was found in tablets of brand must investment for R&D and
matography coupled with X and injectable of brand Y QC labs.
PDA and Acquity QDa. After only, but no other USP-speci-
analysis, we processed the fied impurities have been Contact details
data using Empower CDS found in any samples. We also [email protected]
software and compared the

To subscribe: [email protected] EXPRESS PHARMA 111

December 1-15, 2017

CPhI & P-MEC INDIA 2017 SPECIAL

Detection methods in HP-TLC (Part I)

TB Thite, Sr Manager (Lab),Anchrom Enterprises India,gives an insight about the features of HP-TLC

TRADITIONALLY, qualitative ‘CHROMATOGRAM’TYPE 1 PLATE WITH SEPARATED SAMPLES
and quantitative detection and
evaluation in High Performance white light. This documentation ‘CHROMATOGRAM’TYPE 2 IMAGE OF SAMPLES ON PLATE
Thin Layer Chromatography under GLP, when handled
(HP-TLC) is done by evaluating through HP-TLC software, en- ‘CHROMATOGRAM TYPE3PLATESCANOFSAMPLESONPLATE UV down to 190nm.
the chromatographed plate un- ables comparative evaluation of In research labs, it is com-
der UV (absorbance) or fluores- reference and sample, qualita- HP-TLC. Modern PCD reagent erates more chromatograms!
cence (emission). Visible light tively (identification) and semi- spraying machines require only Where a HP-TLC scanner is mon to apply same sample on
was used to evaluate coloured quantitatively (dilution), as per 2-4ml reagent and generate an available, visualisation may not same plate on multiple 'tracks'
fractions, usually after post- regulatory requirements. uniform mist, leading to high be necessary unless the frac- and then evaluate all tracks with
chromatography derivatisation quality derivatisation. PCD gen- tion(s) of interest do not absorb same detection technique as
(PCD). In Part I of the series, the Next the same ‘plate chro- well as each 'track' by a different
above technique will be de- matogram’ is scanned in a scan- detection mode!! All this without
scribed while in Part II discus- ner, where a monochromatic repeating chromatography!
sions will be held on HP- beam of chosen wavelength (be-
TLC/MS-IR-NMR and Effect tween 190-800nm) travels over No wonder HP-TLC is called
Directed Analysis. each sample track, detecting ab- the Cindrella of Chromatogra-
sorbance and, generating ‘scan phy. HP-TLC proves to be a sim-
At the outset, it must be chromatograms.’ UV ab- ple technique with many unique
noted that in HP-TLC, after sep- sorbance spectra of selected or advantages, particularly with re-
aration, the 'chromatogram' re- all peaks are also recorded. Then spect to data obtainable from
mains on the plate and does not the 'plate chromatogram' is samples, high throughput and
go to waste. Only in HP-TLC, the scanned similarly for fluores- low cost of analysis. Further in-
term 'chromatogram' can have cence with 366nm as incident formation can be obtained from
three meanings viz. a) separated light and a visible light transmit- the same plate, using MS, IR,
samples embedded on the plate ting filter placed before the pho- NMR and Effect Directed Analy-
b) its photographic image(s) c) tomultiplier detector. In HP-TLC sis, which will be described in
its 'scans.' Therefore, HP-TLC scanner, since the photomulti- Part II.
'chromatogram' can be evalu- plier detector is an angle to the
ated by the eye as well as by in- light source the emission can be
strumental means. The ‘scan’ selectively measured, without
data is similar to GC-LC output, interference from the light
in form of peaks. source. No separate fluores-
cence detector is required. A big
Two things to unlearn here advantage! All the above are
are that one has to 'forget prac- non-destructive methods of de-
tice of TLC' because it is not in- tection that leave the ‘chro-
strumental and has no univer- matograms’ intact! Another big
sally agreed methodology. LC advantage!!
users must get used to parallel
processing of multiple and dif- A chromatographed sample
ferent samples and 'stored' chro- (on multiple tracks) can be de-
matograms. rivatised i.e. reacted on the plate
with one or more derivatisation
The ‘plate’ i.e. separating reagents in-situ to get a treasure
medium in HP-TLC is 20 x 10cm of additional specific and high
in size, coated with a 0.2mm sensitivity information about the
thick layer of 5µm adsorbent on a sample; PCD is very simple, ap-
flat support. Silica gel with fluo- plicable to every sample and
rescent indicator F254 is the ad- needs no special accessories in
sorbent of choice, unless proved
unsuitable.

Once the chromatographic
development is over and the
plate dried, the HP-TLC 'chro-
matogram' on plate is visually
evaluated under UV 366nm for
native fluorescence and then UV
254nm for substances absorbing
around that region against a flu-
orescent green background.
Next, the 'chromatogram' is im-
age documented in a table top
dark room, again under UV
254nm and 366nm and also

112 EXPRESS PHARMA

December 1-15, 2017

HP-TLC

THE DATA-INTENSIVE TECHNIQUE!

HP-TLC “chromatograms” remain on the plate, unlike GC-LC.
Several non-destructive detection methods can therefore be
used and followed by destructive ones on the same plate.
Each detection mode gives different information. Given
below is the data obtainable from one “plate”.

HP-TLC plate with 15 samples (UV 254nm)

Data Set 1 From Imager Data Set 3 From Scanner Data Set 6

Images Documentation 254nm, Fluorescence scan - incident 366nm, Effect Directed Analysis
366nm, visible light emit 400-800nm

Anti-oxidant (DPPH)

Data Set 4 From PCD + Imager Toxic
Fractions
Post Chromatography Derivatisation (PCD) Detection

Anti-bacterial
fractions detection

Data Set 2 From Scanner Before After

UV, Vis. Absorbance Data Set 5 Undesired estrogenic substances

Quantitative scanning HP-TLC/MS Hyphenation & IR, NMR Data Set 7

UV Abs. spectra 2D Chromatography

3-D plot - multiwavel. scans MS IR, NMR Simple. With same or different
mobile phases

HP-TLC Specialist! For live demo, details & free training:
[email protected]

9833830899/9833830898

CPhI & P-MEC INDIA 2017 SPECIAL

Louis Roy,President,OPTEL GROUP bags
Quebec Entrepreneur OfTheYearAward

The awards recognise aspects such as integrity, leadership, entrepreneurship, vision, as well as
the financial performance

LOUIS ROY, President, OP- and encourages us to do what
TEL GROUP, was presented we do best: work towards a
with two Entrepreneur of the more sustainable world for fu-
Year Awards by EY, the first ture generations,” declares
in the Business Products and Roy.
Services category, and the
second covering the entire “This cause has always
province of Quebec. These meant a lot to me and it’s the
awards recognise aspects reason I created OPTEL. I
such as integrity, leadership, wanted to be a socially re-
entrepreneurship, vision, sponsible entrepreneur work-
as well as the financial ing for the good of the planet.
performance. At OPTEL, our main goal is to
solve problems rather than
“If I received these awards create them. Our personalised
today, it’s thanks to the team solutions are developed in line
behind me, who supports my with these values and they
vision and works relentlessly aim to meet customer needs
to meet our common goal. The while protecting consumers
awards are proof that we’re as well as the environment,”
not the only ones who believe adds Roy.
in our mission and that the
business community supports EP News Bureau

OPTELGroup bags loan worth CAD $68 m from
Desjardins Group

The loan will allow OPTEL Group to extend its traceability service offer as well as diversify its
activities in the healthcare, medical devices and R&D fields as well as in other various field

OPTEL GROUP, a leading its usual markets – pharma- world,” says Louis Roy, they the leading cooperative fi-
global provider of traceability ceuticals. OPTEL already nancial group in Canada, but
systems, announced that Des- owns 25 per cent of the global OPTEL is President, OPTEL Group. Desjardins also stands out
jardins Group is providing the market share for the health- “Desjardins is pleased to with its commitment, financial
company with CAD $68 million care Track & Trace hardware strength and contribution to
in loans in order to support its systems market and keeps ex- constantly grant these loans, because sustainable prosperity. Since
growth and expansion plans. hibiting its proficiency in se- we trust the OPTEL brand Desjardins’ and OPTEL’s val-
curing the medical products’ ues are perfectly aligned, this
Such financial support will supply chain. committing to completely. The financial sit- collaboration between two
allow OPTEL to extend its attain new uation of the company is ex- leaders in their respective field
traceability service offer as “OPTEL is always looking cellent and it was very im- is entirely logical and will help
well as diversify its activities in to push limits and rise to next- OPTEL maintain its present
the healthcare, medical de- level, more difficult challenges. objectives, on a portant to us to support momentum, by continuing de-
vices and research and devel- These issues that humanity is their expansion and veloping solutions perfectly
opment fields as well as in facing, they require innovative adapted to its customers’
other various fields, such as solutions. This support from bigger scale, and growth,” adds Robert needs and able to solve real is-
food and natural resources. Desjardins will allow us to go Bastien, VP, Business Ser- sues.
This assistance also aims to even further in our growth, by
improve OPTEL’s predomi- entering new, crucial markets Desjardins Group vices at Desjardins Group. EP News Bureau
nance and influence in one of to create a more sustainable OPTEL is constantly
is a critical ally to committing to attain new

make them a objectives, on a bigger scale,
and Desjardins Group is a

reality critical ally to make them a
reality. Indeed, not only are

114 EXPRESS PHARMA

December 1-15, 2017

www.fsie.in

MAKE YOUR BUSINESS

SECURED & FIRE PROOF

efosArtsaFfibiprrleeeisrpahtrnhmedeceLaNniufatesttiiSoohannafave&eltsByteouacilcluldocrimiontmygplnCmyoowerdmriecthsia.alll

FIND LATEST TECHNOLOGIES,
DEVELOPMENTS & APPLICATIONS FOR

FIRE SAFETY AND SECURITY

For more details, Contact: *Show Timings: Organised By:

Apurba Biswas 22 February 2018: 10am – 6:00pm
+91-97690 51748 23 February 2018: 10am – 6:00pm
[email protected] 24 February 2018: 10am – 5:00pm

*Entry restricted to trade professionals only. Children below 18 years of age are not allowed. Organiser reserves the right to entry.

CPhI & P-MEC INDIA 2017 SPECIAL

CPhI Worldwide report highlights unpredictability
in CDMO growth over next five years

Flow chemistry, fermentation, repatriation of overseas funds, oncology and API/product
integration to grow, but the rate of change remains unclear

CPHI WORLDWIDE, which purchase of Cook Pharmica]. simplifying the supply chain lyophilised/injectable products we expect to see more multi-
was recently held in Frankfurt The only large merger with CDMOs enable VCs to have a and antibody drug conjugation step flow processes per-
announced the findings of part the intention of creating a longer runway for investments, as the sector arms itself for the formed,” Dr Chen added.
i of the 5th edition of the CPhI more integrated outsourcing and the potential for faster re- next wave of drug candidates.
Annual Report, which focusses model was the Lonza acquisi- turns, whilst also reducing The report also pointed to
on the immediate and long- tion of Capsugel. However, risk. Sam Tadayon, Executive the increased role fermenta-
term trends in pharmaceutical Roth predicts that smaller Director and Dr Minzhang tion is set to have in bringing
outsourcing. The exhibition, as scale buys to expand their cur- “From pharma’s perspec- Chen, CEO, STA Pharmaceuti- newer types of drugs through
the world’s largest pharma rent capabilities are far more tive, this enables them to con- cal, state that flow chemistry the development pipeline. Bio-
event, is a key bellwether of likely by CDMOs, whilst ‘ex- centrate on broadening the has the potential to revolu- con’s, Prasad highlighted the
global trends and the indus- US CDMOs’ may try to boost number of drug discovery pro- tionise and modernise pharma role it will have in helping to
try’s overall strength. This first their US presence by acquir- grammes they work on simul- processes, but cautions that commercialise new vaccines,
part of the report features the ing an existing provider or an taneously and should expedite overall, the industry is still a biologics and even problematic
contributions of four industry available pharma facility. new drugs to market. In fact, full 50-years behind the bulk areas like the creation of new
experts — Gil Roth President, chemicals industry on the im- antibiotics that overcome an-
PBOA; Vivek Sharma, CEO, Roth explained at length The overall plementation of this technol- timicrobial resistance. In par-
Piramal Pharma Solutions; the relative unpredictability of findings reveal ogy. They note that implement- ticular, the technology holds
BSV Prasad, Sr VP & Head, the current pharma climate, that the trend ing changes at the commercial the key to fully leveraging the
Small Molecules Business, considering the unclear plans towards the stage can be limited by regula- advances in recombinant DNA
Biocon and Sam Tadayon, of the current US administra- integration of tory challenges. However, and will be beneficial to drug
Executive Director and Dr tion. For instance, there has pharma those companies that invest discovery programmes involv-
Minzhang Chen, CEO, STA been a keen political desire in outsourcing early in this technology will ing stem cells and even gene
Pharmaceutical. the US to reduce drug prices, continues, with benefit from more environ- therapy vectors. The resur-
but with very little indication single source mentally friendly production, gence of interest in antibiotic
The overall findings reveal of policy, leaving pharma com- providers in and potentially double digit development and therapeutic
that the trend towards the in- panies and ‘CDMOs in the terms of cost savings at commercial vaccines is also forecast to
tegration of pharma outsourc- dark as to decisions that may development scale. To expedite the process drive increased demand over
ing continues, with single very well disrupt their entire increasingly and advance the technology the medium term.
source providers in terms of business model’. Another sought more quickly, an increased
development increasingly knock-on industry effect could number of specialised chemi- Andreas Mavrommatis,
sought. However, acquisitions result from a ‘tax holiday’ in over the next two to five years, cal engineering teams will be Global Marketing Director,
in the future will not be domi- which big pharma reinvests we will increasingly see more needed. Initial development of UBM EMEA, said, “In the last
nated by big deals and large large amounts of repatriated symbiotic relationships be- flow chemistry production oc- five years, CPhI has grown its
mergers, but rather smaller capital in its own domestic fa- tween pharma and CDMOs – curred at big pharma facilities, attendee base enormously, but
commentary services and cilities, particularly biologics with even capital and risk but increasingly, we will see during the same period, the
niche technologies to fill spe- sites, with negative connota- sharing deals,” added Sharma. these outsourced by the pio- event has established itself as
cific technology asset gaps. tions for the growing CDMO He concluded that in terms of neers to their strategic CDMO a vital channel for industry re-
Furthermore, the industry is industry. He added, “Given the specific products classes, in partners. search, analysis and trends.
anticipating a large increase in focus on reducing legal immi- the immediate future, oncol- This year our Annual Report
the use of flow chemistry and gration in the US, there is ad- ogy continues to grow quickly “The message here is clear: experts have highlighted flow
fermentation technologies – ditionally the strong possibil- as pharma and biotech see for flow chemistry to deliver on chemistry, integrated CDMOs,
but resistance to change may ity of a shift in the talent pool medium-term potential suc- its huge promise, pharma and and potential threats to out-
slow adoption significantly. of pharma employees to other cess. It is therefore likely that CDMOs need to build the plat- sourcing from a changing busi-
more welcoming nations, CDMO’s will invest in parallel form into the early phase ness environment. I would en-
The new US Government which may impact the domes- areas such as high potency process R&D of innovative API courage all attendees to read a
administration, the longer- tic wages.” API manufacture, programmes,” commented Dr copy of the findings and also
term implications of drug pric- Tadayon. “In the next five use CPhI Worldwide as a
ing, and big pharma income Vivek Sharma, CEO, Pira- years, however, more advanced sounding board to explore how
repartitions are highlighted as mal Pharma Solutions, fore- flow technologies will be devel- they might be able to work
the key unknowns and risks for casts that the long heralded oped and more companies will more efficiently, grow rev-
CDMO sector. one-stop-shop CDMO is now be developing continuous enues and explore the latest
coming to fruition in the indus- processes, while the existing development and manufactur-
Gil Roth, President, try, with biotechs a clear bene- scientists will build up more ing technologies. As well as an
Pharma and Biopharma Out- ficiary of this trend. Echoing experience in this area. As a opportunity to meet existing
sourcing Association, suggests Roth’s perspective, he argues result, we should expect a customers, CPhI provides a
that the consolidation ex- that over the next few years we wider range of reactions to be steer on tomorrow’s develop-
pected of the CMO/CDMO will see ‘CDMOs in niche areas processed through flow, and a ments and helps you explore
sector to improve the effi- forward and back integrate’, lower bar to be established for the right partners to maximise
ciency of outsourcing has not offering more integrated value selecting a process to be oper- the value in your business.”
yet panned out in 2017 [this chains to customers. In fact, by ated in flow. During this time,
was written prior to Catalent’s EP News Bureau

116 EXPRESS PHARMA

December 1-15, 2017

CPhI & P-MEC INDIA 2017 SPECIAL

CPhI Worldwide report forewarns of intense battle between
innovators and biogeneric companies for next three years

Experts state pharma regulation will shift due to increased data dependence, warn regulatory
oversight is slowing six sigma adoption, and forecast increased generic options 2025 onwards

CPHI WORLDWIDE, organ- should now accelerate. suggests in his article that the PIC/S by 50 regulatory enti- tiative – remains. Utilising the
ised by UBM, announced the Dilip G Shah, CEO, Vision there are still good opportuni- ties (with a further 70 expected constructive development the-
findings of final section (part ties for biosimilars in the in- to join by 2020). There have ory of adult human develop-
iii) of the 5th edition of the CPhI Consulting Group, discusses dustry. In the past, he claims, also been important legislation ment, he explores how Amgen
Annual Report, which focusses how the intense battle between biosimilars were often viewed changes, for example the 21st (as a case study) reached six
on the immediate and long- innovators and biogeneric as a ‘risky venture’ for pharma Century Cures Act in late 2016 sigma with an error rate of just
term trends in pharmaceutical companies is likely to play out companies, but now could be authorised new drug and de- 3.4 defects per million opportu-
data, regulation, generics and over the next three years, ex- the ideal time to invest. He vice manufacturers to utilise nities. Ajaz stresses that much
biosimilars. plaining the tide is now gradu- added, “uptake of the latest real-life data to establish drug of the sector is held at a devel-
ally turning in favour of biosimilars in Europe is ex- safety and efficacy for FDA ap- opment stage – “socialised
The full report was pub- generic companies thanks to tremely positive and is starting proval. mind.” Systems orientation be-
lished live from CPhI World- pressure from patients on gov- to track the dynamics of small gins at the ‘self-authored’ stage
wide in Frankfurt amongst ernments to act. Shah states molecule products.” As a consequence of new of development. The Amgen
more than 42,000 executives, that innovators are known to high-throughput technology, case illustrates how this can be
with four experts in data, regu- impede the progress of bio- Sheppard emphasises that notably next generation se- achieved. However, in the syn-
lation, generics and biosimilars generic companies in generic it is even not too late for quencing, Chatterjee says that thetic drug product sector, the
— Dilip G Shah, Alan Shep- and biosimilar production pharma companies that have the role of data in illustrating legacy practices – such as the
pard, Bikash Chatterjee, and through morally dubious prac- yet to get involved in the performance and compliance use of compendial test methods
Ajaz S Hussain – giving their for batch release testing – and
views on near- and long- term The overall findings warn that the FDA’s the inherent uncertainty in
trends across the industry. approach to achieving six sigma is currently measurement systems for
failing, encouraging regulatory oversight, physical attributes, such as dis-
The overall findings warn rather than the self-adoption of solution tests, can serve as a
that the FDA’s approach to continuous quality systems by industry 'self-imposed' 2-3 sigma bar-
achieving six sigma is currently rier. This barrier contributes to
failing, encouraging regulatory tices, yet he does not believe biosimilar market: “As with will continue to increase over high OOS rates and high rates
oversight, rather than the self- these methods will be fruitful small chemical molecules the next decade. Improve- of invalidated OOS, which is a
adoption of continuous quality in slowing down the progress there now exists biosimilar de- ments in big data analytics will metric that the FDA is cur-
systems by industry. A positive of biogenerics. He explains, velopers who are seeking part- be crucial in highlighting the rently seeking from industry.
impact, however, was identified “The innovator companies will ners for marketing and distri- most suitable candidate drugs Often this is not appreciated,
in the regulatory approach to face increasing pressure to en- bution and contract more quickly from e-clinical, and it serves as a blind spot.
data standards and analysis, sure access to medicines at af- manufacturing organisations lifestyle diagnostics and digital
which will see drug discovery fordable prices. But now the with biosimilar capabilities. If health initiatives. However, Chris Kilbee, Group Direc-
and patient treatment revolu- regulators and the govern- that is not an option then port- Chatterjee highlighted cyber tor, Pharma Portfolio, UBM
tionised over the next decade. ments will take on the innova- folio growth from small chemi- security as a potential risk fac- EMEA said, “Now in its fifth
For example, investments in tors and force them to facili- cal molecules will still offer op- tor, especially as the industry year, the CPhI Annual Report
handling big data will allow the tate development of biogeneric portunities. The recent increases dependence on pa- delivers detailed perspectives
industry to mine lost nuggets of versions over the next two to increase in launches of small tient data for drug develop- on the most advanced pharma
insight into historical perform- three years.” chemical products forecasted ment. He added, “The indus- practices, analyses and future
ance, whilst also enabling in- to be potential blockbuster try’s ability to manage the predictions. CPhI Worldwide is
sight from e-clinical and post- Shah added, “FDA Com- molecules will offer significant constantly evolving threats to pharma’s one true global event,
market vigilance initiatives missioner’s recent statement generic opportunities in the data management and in- with a reputation as the place
more effectively. will encourage biogeneric com- years beyond 2025.” tegrity will define how we de- to do business and learn the
panies to be more aggressive velop new drug therapies in developments of tomorrow.
The report also noted that, than they have been so far. The Bikash Chatterjee, Presi- the future.” This report, like the event, pro-
despite what one expert de- FTC has already conveyed that dent and Chief Science Officer, vides insight on all parts of the
scribes as the ‘abusive’ and it is contemplating launching a Pharmatech Associates, ar- Ajaz S Hussain, Founder of pharma supply chain. In part
‘unethical’ antics of innovator formal investigation. Thus, gues that the emergence of a Insight, Advice & Solutions, ex- iii, experts identified exciting
companies, the development of both drug regulator and the global marketplace with shared plores why a perpetual gap be- developments in high-through-
biogenerics is continuing competition authorities will be regulatory compliance is one of tween what we know and what put sequencing, potential new
apace. Furthermore, with the on the same side.” many factors driving change in we can practice and implement methods to achieve regulatory
anticipated harmonisation of pharma regulation. A key ele- – more than a decade after the excellence and changing dy-
biosimilar regulatory guide- Alan Sheppard, Principal of ment to this is the adoption of launch of FDA’s 21st century ini- namics across the biosimilars
lines – a common dossier for Global Generics, IMS Health, marketplace. I would encour-
use both in the US and Europe age all of our attendees at CPhI
is currently under discussion – Worldwide and the wider in-
and an overall increase in play- dustry to study the report’s full
ers in the market, the dynam- findings closely.”
ics of the biosimilar market are
shifting towards congruence EP News Bureau
with the generics and adoption

To subscribe: [email protected] EXPRESS PHARMA 117

December 1-15, 2017

CPhI & P-MEC INDIA 2017 SPECIAL

LANXESS expands its CSR outreach in Nagda

Signs MoU with Nagda Municipal Corporation for support, undertakes maintenance of overhead
water tank in Mehatwas, supports development and maintenance of municipal garden in Nagda

LANXESS INDIA, a leading stituency, Neelanjan Banerjee, nicipal garden, LANXESS In- This is expected to directly solar panels, solar bulbs and
speciality chemicals company Senior Executive Director, dia will ensure structuring of benefit a population of over maintenance for a period of
has taken another major step LANXESS India, Sanjay Singh, the fencing, grass beautifica- 2400 in the region.Contribut- three years. On this occasion,
towards creating a sustainable Site Head, Nagda, LANXESS tion and planting of saplings. ing towards making the planet Banerjee said, “LANXESS
environment in and around India and other esteemed dig- With an aim to ensure better greener, LANXESS India will takes its social responsibility
Nagda by undertaking three nitaries from the state and lo- infrastructure for distribution be undertaking the installation projects in true spirit and has
projects as part of its corpo- cal administration. These proj- of the current water supply of solar street lights in Mehat- been relentless in its efforts of
rate social responsibility. The ects are in line with LANXESS’ system in the town, LANXESS was and Durgapura wherein, making a positive and mean-
company signed a memoran- vision for sustainable develop- will support in the repair and the company will support the ingful change in the lives of the
dum of understanding with the ment and a better quality of life renovation of the pipeline dis- municipal corporation with in- people in and around Nagda. In
Nagda Municipal corporation for the people of the region. As tribution and strengthening of stallation of 25 solar street the current fiscal year itself,
wherein it committed to un- part of the maintenance and column structure of the over- lights. The installation will in- the company has supported the
dertake the maintenance of development of the Nagda mu- head water tank in Mehatwas. clude pole installation, battery, region through five different
overhead water tank in Mehat- CSR projects worth around
was, development and mainte- LANXESS LEADS IN CLIMATE PROTECTION SCORING `50 lakhs. The three new proj-
nance of Nagda municipal gar- ects launched today assert our
den and installation of solar ◗ Group among the top five per cent of the compa- veyed by the initiative. commitment towards the re-
street lights in Mehatwas and nies rated worldwide Commenting on the achievement, Neelanjan gion’s welfare and the com-
Durgapura. ◗ Inclusion in the Climate A List of the non-profit pany’s vision of a sustainable
organisation CDP Banerjee, Senior Executive Director, LANXESS environment.” Commenting on
This announcement follows ◗ Broad contribution to UN sustainable develop- India said, “It is a matter of pride for us at the projects, Singh said,
the company’s CSR outreach ment goals LANXESS to be included in the Climate A list. “LANXESS India has taken
projects launched last month As this listing reiterates our commitment to do- these initiatives as a step for-
wherein LANXESS committed At the United Nations World Development ing business across the globe in a sustainable ward to sustainability in the re-
its support to the Nagda gov- Information Day, the international climate pro- manner and gives us the confidence that we are gion of Nagda. With the cur-
ernment college by way of e- tection initiative CDP (formerly Carbon Disclo- on the right path in addressing our sustainabil- rent environmental conditions,
learning tools and support of a sure Project) honoured speciality chemicals ity goals and targets.” sustainable development is the
sonography machine to the company LANXESS. solution for a healthier lifestyle.
Nagda Civil hospital. The Even beyond climate protection, LANXESS’s Through these projects, we
three-year long MoU was The Cologne-based company once again business activities, products and corporate ini- hope to improve the quality of
signed in a ceremony held at achieved the highest score in this year’s evalua- tiatives contribute effectively to each of the 17 living for the people of Nagda. I
the Nagda community hall in tion and is therefore listed in the CDP’s Climate A sustainable development goals, which the United also thank the Municipal Cor-
the presence of Ashok Malviya List. With this list, CDP recognises companies’ Nations draws attention to every year on Octo- poration of Nagda for seeing
Chairperson Municipal Coun- efforts to cut emissions, mitigate climate risks ber 24. They include clean watersolutions as well merit in our efforts and sup-
cil and Dilip Singh Shekhawat and develop the low-carbon economy. As part of as an educational initiative that has already sup- porting us.”
Member of Legislative Assem- the Climate A List, LANXESS is among the top ported hundreds of thousands of children, young
bly Khachrod-Nagda Con- five per cent of several thousand companies sur- people and young adults around the world. EP News Bureau

DKSH to promote pharma portfolio at CPhI India 2017

DKSH will showcase an exciting portfolio of pharma ingredients, innovative solutions and
concepts, together with its renowned key clients

DKSH’S BUSINESS Unit Per- experts to meet, learn, share Plasdone, Klucel, Benecel, Pharma 8/30/50 and Intermediates for pharma-
formance Materials, a leading ideas and drive business Blanose, Aqualon Ethly cellu- ◗ JMC: Sodium Saccharin 6 per ceutical synthesis
ingredients and speciality throughout the year. lose, Aquarius coatings systems cent and 15 per cent
chemicals distributor and and Natrosol ◗ Precheza: Pretiox AV 01 PhG “Exhibiting again at CPhI In-
provider of market expansion DKSH will exhibit at stand ◗ Crest: Various grades of Cellu- ◗ Daicel: Granfiller (co- dia, together with our valued
services, will exhibit at CPhI In- A15 in hall 1 at the Bombay Ex- crest (MCC) and Crestcross, processed excipient) GNF- business partners, will allow us
dia 2017 in Mumbai, India, from hibition Centre, where senior Crestadd, Gelmac, Lubricrest to attract new business and con-
November 28-30. The event is executives from DKSH and its and Rapigel D211/GNF D215 tinue to contribute to the world
South Asia’s leading platform valued business partners will be ◗ Symega: Pharmaceutical ◗ Wacker: Cavamax W8, Cavac- of innovative pharmaceutical in-
for pharma ingredient product present throughout the show to flavour (liquid form) and func- urcumin and HTEssence gredients. We look forward to
manufacturers, suppliers as promote their extensive tional flavour ◗ Horphag: Pycnogenol and another successful show this
well as buyers and provides a pharma ingredients portfolios, ◗ Stepan: Stepanol WA 100 Robuvit year,” commented Atul Na-
unique environment for pharma which include: ◗ Mondo Minerals: Microtalc ◗ Other sources: Active Phar- garkar, MD, DKSH India.
◗ Ashland: Various grades of maceutical Ingredients (APIs)
EP News Bureau

118 EXPRESS PHARMA

December 1-15, 2017

CPhI & P-MEC INDIA 2017 SPECIAL

LANXESS Urethane Systems to enhance
research on next generation materials

Collaborates with Polymer Science and Engineering department of University of
Massachusetts Amherst

THE URETHANE Systems demic collaboration for Ure-
thane Systems is scientist
business unit of speciality In the long run, LANXESS expects cost savings Alan Lesser from the Univer-
through sophisticated, highly efficient solutions sity of Massachusetts
chemicals company as well as benefits in business competition by Amherst, who is a world ex-
using progressive technologies and the recruiting pert in deformation and frac-
LANXESS decided to join the of qualified specialists ture of polymers and compos-
ites. His research focusses on
Center for UMass/Industry strength, durability, and mi-
cromechanics of polymer
Research on Polymers blends and composites, nano
and molecular composites,
(CUMIRP) at the University constructive modelling of
polymers in complex stress
of Massachusetts Amherst, states as well as unique pro-
cessing methods and multi-
USA, in order to enhance its functional additives. As of
2016, the group is focussing on
scientific research on next next-generation additive man-
ufacturing formulations. Fur-
generation materials. thermore, Lesser is editor-in-
chief for the technical media
CUMIRP acts as a cross- property relationships to de- Dr Polina Ware, Head of gain potential cost savings and Polymer Engineering and Sci-
velop new process methods Global Research and Develop- business growth though new ence Journal, Polymer Com-
roads where university re- and new chemistries. The col- ment, LANXESS Urethane Sys- product innovation.” posites, and Journal of Vinyl &
laboration will come into ef- tems business unit, “The re- Additives Technology.
search and education meet fect on October 2017. search clusters are targeted The Polymer Science and
towards specific research areas Engineering Department at EP News Bureau
with industrial partners in In the long run, LANXESS and allow small team dynamics the University of Massachu-
expects cost savings through and interactions as well as col- setts Amherst is the leading in-
polymer materials, engineer- sophisticated, highly efficient laboration between industrial stitute on polymer science in
solutions as well as benefits in members, faculty and students. the US and one of the largest
ing and processing to leverage business competition by using This team-oriented approach academic centres for polymer
progressive technologies and fosters cross-industry collabora- research in the world, with
resources and foster collabo- the recruiting of qualified spe- tion as well as gives us access to currently more than 200 scien-
cialists. Furthermore, access top experts in polymer science tists, $24 million in instrumen-
ration. LANXESS will join to other companies who could as consultants. As members of tation and over 600 doctoral
be potential partners and/or Cluster M and F, we expect to degrees awarded.
Flammability Cluster (Cluster customers will be provided.
A key figure in the aca-
F) and Mechanical Properties

& Additive Manufacturing

Cluster (Cluster M). This col-

laboration targets the devel-

opment of novelurethane ma-

terials, it focusses on in-depth

understating of structure-

Clariant packaging solutions extend shelf life of
oxygen and moisture-sensitive probiotics

Solutions include ‘active’ scavengers and ‘passive’ barriers

CLARIANT, A world leader in otics along with their effective- blow-molded containers of- ishes that accept pharmaceu- ant offers PharmaKeep oxygen
speciality chemicals, with its ness,” explained Stephane tical screw caps produced ac- scavengers, which are humid-
healthcare packaging business Rault, Product Manager, Clari- fers several times the oxygen- cording to SP400. ity-neutral and combined with
unit, announces a combination ant Healthcare Packaging. a desiccant that simultane-
of packaging solutions that pro- “The optimal way to protect barrier protection of stan- Oxygen scavengers, typi- ously adsorbs moisture.
tect the potency and extend the the most sensitive probiotics cally in the form of canisters,
shelf life of probiotics in nu- often involves a combination of dard, single-layer packets, or cap inserts, provide Clariant also manufactures
traceutical products by inhibit- ‘active’ and ‘passive’ solutions.” active protection against oxy- a full line of silica gel and mo-
ing their exposure to damaging polyethylene bottles, plus en- gen exposure, including resid- lecular sieve desiccant canis-
oxygen, moisture and light. Passive solutions are the ual headspace oxygen present ters and packets that adsorb
first line of defense for probi- hanced protection against the during packaging or any fugi- water vapor to protect pack-
“As probiotics are living otics. These can include pack- tive oxygen molecules that aged pharmaceuticals, nu-
‘good’ microorganisms, it is es- ages with strong barrier permeation of moisture and make ingress to the package traceuticals, and other prod-
sential to protect them from properties, such as Clariant’s during its shelf life. Scavengers ucts from damage due to
exposure to elements – oxygen, Oxy-Guard bottles. According UV light. Oxy-Guard bottles are inserted directly into the excess moisture.
moisture, and UV light – that to Rault, the unique structure package or bottle where they
can damage or kill the probi- of these six-layer, extrusion are compliant with US FDA actively absorb oxygen. Clari- EP News Bureau

and EU regulations for use in

pharmaceutical and nu-

traceutical applications and

are covered by a Drug Master

File (DMF). Oxy-Guard bot-

tles are available in a range of

standard sizes, with neck fin-

To subscribe: [email protected] EXPRESS PHARMA 119

December 1-15, 2017

CPhI & P-MEC INDIA 2017 SPECIAL

Translational Research Institute,Australia
leads way with Livecyte inAPAC

Livecyte enables quantitative, label free, live cell imaging and analysis of single and multiple cell
types in heterogeneous cell populations using ptychographic quantitative phase imaging

THE TRANSLATIONAL Re- After installation a Livecyte system at TRI, Phasefocus Biological tive phase imaging (QPI). croscopy core facility at TRI.
search Institute (TRI), Brisbane Applications Specialist, Richard Kasprowicz runs through its Requiring only low-level illu- Senior microscopy scientist
has become the first centre in operation with Alex Stevenson from the TRI Melanoma Research Group
Australia and the Asia Pacific mination, Livecyte provides a Dr Sandrine Roy, who man-
region to adopt the Livecyte Cell clinical issues. live cell imaging and analysis of gentle experimental environ- ages the facility commented,
Imaging and Analysis system. Developed by UK-based single and multiple cell types in ment which mimics the behav- “The label-free imaging poten-
heterogeneous cell populations iour of cells in 'real life' making tial for primary cell studies is
TRI was formed to enhance company Phasefocus, Livecyte using ptychographic quantita- it suitable for more clinically very exciting in tracking cell
collaboration between science, enables quantitative, label free, and physiologically relevant pri- behaviour with minimal inter-
healthcare and industry with mary and stem cell populations, ference and we are all really
the purpose of accelerating the alongside traditional cell assays. excited to have such a power-
application of innovative scien- ful automated system to help
tific research to improve health- Prof Brian Gabrielli, who with the data analysis.”
care outcomes. leads the Melanoma Research
team, Mater Research saw the Tracey Zimmermann,
The Institute, derived from a capabilities of Livecyte first- Phasefocus VP Global Sales
partnership between Queens- hand, during a visit to the Uni- added, “We are delighted by
land Health; Princess Alexandra versity of York, UK and immedi- TRI’s decision to purchase Live-
Hospital, University of Queens- ately recognised its potential to cyte for their microscopy facil-
land, Queensland University of gain a better understanding of ity. This is a significant result for
Technology, Mater Research cell cycle defects associated Phasefocus and we have great
and its health partner DSM bio- with melanoma. expectations for Livecyte in the
logics, provides both laboratory Asia Pacific region, supported
facilities and resources to aid the Following a review of the sys- by the achievements of the re-
research community in develop- tem’s functionality, funding was searchers in Brisbane.”
ing solutions which address key then successfully sought to pro-
cure Livecyte for the Mi- EP News Bureau

Noramco introduces turnkey approach to
cannabinoid APIs at CPhI Worldwide

The company has obtained patents for chemical synthesis of Dronabinol, Cannabidiol and
derivatives in high yield and high stereospecificity

NORAMCO IS moving for- today pharmaceutical compa- of Dronabinol, Cannabidiol, Dronabinol in sesame oil rial for clinical trials from the
ward with a broad offering of nies require a robust partner and derivatives in high yield and ethanol US will be available in the first
clinical- to commercial-scale to ensure regulatory approval and high stereospecificity. quarter of 2018.
cannabinoid APIs for branded and commercial supply,” said These patents allow produc- Noramco maintains a Drug
and generic pharmaceuticals. Bill Grubb, Vice President tion of high-purity, stable syn- Master File (DMF) for high-pu- Cannabidiol
The comprehensive offering Global Strategy and Innova- thetic material. rity synthetic Dronabinol API
includes everything a drug tion, Noramco. in a solution of 20 per cent Leveraging eight years of
manufacturer requires to ad- “Pharma companies that sesame oil. The API is pro- global supply chain expertise
vance cannabinoid-based APIs “To help clinicians and drug choose to work with us in duced in Switzerland today via in Dronabinol, Noramco is run-
to finished dosage forms. More development companies cannabinoids can expect supe- a novel synthesis process, and ning a global supply pro-
than 100 active clinical trials progress potentially life- rior quality and secure sup- work is underway to make the gramme for Cannabidiol. In-
are in progress involving changing drug development, plies, starting with a full port- product available from No- cluded in the programme is a
cannabinoids, most focussing we are leveraging assets, ex- folio of API impurity and ramco’s US-based production plan to produce high-purity
on Dronabinol (THC) and pertise, and intellectual prop- reference standards, and con- facilities. Going forward, No- material via a patent-pro-
Cannabidiol (CBD). erty to provide customers a tinuing with samples, clinical ramco also will make Dronabi- tected synthetic route, utilising
sound solution, seamlessly.” material, and commercial- nol available in a 20 per cent assets in the US. Currently,
“Therapeutic benefits are scale supply from facilities in ethanol solution, with initial Noramco supplies GMP sam-
established for several Earlier this year, Noramco Europe and the US,” Grubb synthesis already in progress ples from Europe.
cannabinoid compounds, and announced that it obtained said. in Athens, GA. Full GMP mate-
patents for chemical synthesis EP News Bureau

120 EXPRESS PHARMA

December 1-15, 2017

CPhI & P-MEC INDIA 2017 SPECIAL

Noramco introduces controlled substance
development solutions at CPhI Worldwide

The speciality API producer introduced a comprehensive development-to-manufacturing
platform to provide its customers more technically sound solutions

NORAMCO IS integrating its today provide the framework ment design, operations and needs of its global customers. with Azelis, a value-adding dis-
API development offering to for Noramco as a one-stop re- process safety afford develop- These include the ampheta- tributor with expertise in con-
include all of the technologies source for novel API develop- ers a one-stop location to pro- mine salts, methylphenidate trolled APIs. Azelis maintains
and services that generic and ment and unique dosage form duce parenteral and high-po- hydrochloride and tapentadol application laboratories and
branded pharmaceutical solutions.” tency controlled substances hydrochloride as well as warehouses throughout No-
producers require to advance supported by a rapid response Cannabidiol, Dronabinol, and ramco’s European service area
solutions to market. The spe- Custom synthesis of team to execute against client other related cannabinoids. and is capable of accelerating
ciality API producer intro- controlled APIs needs for clinical-to-commer- product and reference stan-
duced a comprehensive devel- cial APIs. “One of the leading produc- dards delivery. Azelis joins ex-
opment-to-manufacturing Most recently, Noramco up- ers of specialty APIs, Noramco isting distribution partners,
platform to provide its cus- graded its small-volume manu- New Controlled APIs holds both the development Midas and IMCD.
tomers more technically sound facturing suites in the US. The and regulatory expertise re-
solutions, under one roof, with flexible high-containment Noramco, a global controlled- quired to bring virtually any Reference standards port-
less complexity. suites have controls in place to API supplier with 40 years of controlled API to market, any- folio now available online
produce compounds of experience, also continues to where in the world,” Grubb
“Noramco has fine-tuned its OEL<500 µg/m3. Special adap- expand its portfolio of tech- said. “As we further expand our Noramco offers well-charac-
business to serve as a solutions tions in-suite design, equip- nologies to better serve the technology portfolio, our cus- terised, highly purified analyt-
provider” said Jim Mish, CEO tomers may come to us for ical reference standards for
and President. “We now pro- APIs that address a greater di- routine analysis, method vali-
vide all of the expertise and as- versity of medical conditions.” dation and development, com-
sets that customers require to mercial investigations, stability
rapidly advance novel con- Distribution partnership studies and other product de-
trolled API solutions from clin- for Europe velopment activities. Compa-
ical to ready-to-implement nies that hold a DEA license
commercial products,” Mish Earlier this year, Noramco an- may now order impurity refer-
said. nounced a strategic frame- ence standards from Noramco
work to unlock the full poten- directly online from a new
“We are here at CPhI tial of its business by highly secure website. This
Worldwide to showcase the pil- expanding its portfolio and ge- new website provides analysts,
lars of our business that afford ographic reach to better align formulators, and developers
our customers the option to ac- with market needs. To ensure rapid access to more than 175
celerate the development of generic and branded pharma reference standards products
their products in a flexible cus- product makers have access to to accelerate their product de-
tomer friendly manner,” said the company’s expanding port- velopment programmes.
Bill Grubb, VP Global Strategy folio and solutions services
and Innovation. “The an- throughout Europe, Noramco EP News Bureau
nouncements we are making has signed a letter of intent

Noramco, SPI Pharma sign letter of intent

To develop formulation solution packages

NORAMCO AND SPI tions that provide convenience, ages. “Partnering with SPI pharmaceutical customers ment, and implement the tech-
Pharma, a global leader in the compliance, and efficacy for Pharma enables Noramco to with formulation packages al- nology at the facility they
manufacture and supply of such therapeutic indications as bring together API and func- lows Noramco and SPI Pharma choose,” added Grubb.
functional excipient platforms intense pain, opioid addiction, tional excipient science to de- to directly support speed-to-
and drug development serv- and central nervous system liver innovative, patient- market, a reduction in trial- Following a definitive agree-
ices, signed a letter of intent to conditions (epilepsy, migraine, friendly solutions to and-error, product differentia- ment, which is expected in the
develop and license formula- etc.). formulators of finished dosage tion, life-cycle management, next 30 days, testing of a select
tion packages, specifically for forms,” said Bill Grubb, VP and technical/regulatory sup- group of cannabinoid and ad-
implementation by their cus- Noramco has previously Global Strategy and Innova- port. diction treatment APIs in
tomers. The companies intend pledged to help its customers tion. unique dosage forms will com-
to deliver 'ready-to-implement' around the world accelerate “Our customers will have mence to establish proof of
patient-friendly drug formula- pharmaceutical development Grubb went on to say that the ability to work in a fee-for- concept (POC).
with technical solutions pack- going to generic and branded service or royalty arrange-
EP News Bureau

To subscribe: [email protected] EXPRESS PHARMA 121

December 1-15, 2017

CPhI & P-MEC INDIA 2017 SPECIAL

Honeywell Connected PlantTakes center
stage at annual users conference

Honeywell users group EMEA to feature customer presentations, new products and technology
demonstrations

HONEYWELL PROCESS So- dozens of Honeywell- and cus- able the quick and effective multi-vendor, multi-site cyber and food and beverage applica-
lutions and its customers, who tomer-led sessions and techni- adoption of IioT. security that’s scalable to meet tions.
represent some of the biggest cal discussions. customer needs. ◗ ControlEdge, when combined
brands in the industrial space, Some of the technologies on ◗ Safety manager SC provides with Experion, dramatically re-
recently met at The Hague for “The main challenges facing display at HUG included: an 'out of the box' SIL certified duces integration costs for ancil-
the company’s 29th annual manufacturers and plant opera- ◗ Process reliability advisor is safety platform that can be eas- lary plant operations, minimises
EMEA Honeywell Users Group tors today continue to be safety, part of Honeywell Connected ily configured to meet SIL2 and downtime through unified sup-
(HUG). A major portion of the efficiency, reliability, productiv- Plant and uses Honeywell UOP SIL3 applications across the port, decreases risk with embed-
event focussed on Honeywell ity and security,” said Vimal Ka- process models for ongoing plant ranging from small pack- ded cyber security, and lowers
Connected Plant, which is the pur, President, HPS. “The power monitoring, early event detec- aged systems to large distrib- total cost of ownership through
company’s programme that of digitisation and our Honey- tion and mitigation of perform- uted architectures. extended system lifecycle.
helps manufacturers operate well Connected Plant pro- ance issues before they become ◗ Experion Local Control Net- ◗ The conference agenda also in-
their plants more safely, more ef- gramme allows us to address costly. work (LCN) enables customers cluded presentations and panel
ficiently and more reliably by these challenges in new ways by ◗ Maintenance training simula- to use their TPS/TDC invest- discussions from several Honey-
leveraging the power of the In- leveraging the incredible tor is a hands-on demonstration ment as the foundation for incre- well customers including British
dustrial Internet of Things amount of data being produced of the next generation of mixed mental process automation up- Sugar, Saudi Aramco, Shell,
(IIoT). by our customers’ facilities.” reality worker training, which grades for a secure, seamless Qatar Fuel Additives Company,
can enhance skills and reduce integration with Experion PKS. Sarlux Refining & Power, VTTI,
More than 850 delegates Honeywell showcased exam- classroom time. ◗ Experion Batch combines Ex- Gazprom Neft, Linde, and oth-
from across the oil and gas, ples of where Honeywell Con- ◗ Enterprise ICS Cyber Security perion’s distributed control, ers. These presentations cov-
chemical, pulp and paper, and nected Plant has been imple- Solution combines the ICS batch automation, and patent ered a range of topics critical to
metals and mining sectors at- mented and some of the results Shield platform with Risk Man- pending visualisation technology industrial automation.
tended HUG. The event fea- that customers are seeing. At- ager and other Honeywell cyber for a solution optimised for phar-
tures numerous displays of the tendees at HUG experienced a security technologies to provide maceutical, speciality chemical, EP News Bureau
newest technologies, along with range of new technologies and
solutions that can help them en-

New unrivalled capabilities take GC-MS to next level of performance

Enhancements to Thermo Scientific Orbitrap GC-MS Systems offer users unprecedented depth
for comprehensive compound characterisation

UPDATED WITH new capabil- both research and routine labo- is helping us build up an under- and the Exactive GC Orbitrap, to enable identification of chal-
ities in high resolution accurate ratories performing gas chro- standing of disease phenotypes include: lenging compounds. With the
mass (HRAM) GC-MS, the matography mass spectrometry in more detail,” said Jean- ◗ VeV technology that enables addition of Kovats retention in-
Thermo Scientific Orbitrap GC- (GC-MS). “The power of the François Focant, professor and low electron voltage settings to dex to the scoring index of un-
MS systems now give users multi-award winning Orbitrap director of the organic and bio- be used during electron ionisa- knowns, user confidence in com-
across metabolomics, food GC-MS technology has facili- logical analytical chemistry labo- tion (EI) protocols, promoting pound identification is
safety, environmental, pharma tated numerous scientific ad- ratory (OBiAChem), University high mass signals and provid- improved, especially in relation
and toxicology applications high vances and enabled our cus- of Liege, Belgium. ing high sensitivity for com- to isomeric compounds.
levels of accuracy in their data. tomers to break new ground and pounds prone to extensive ◗ The Q Exactive GC Orbitrap is
gain a deeper understanding of “One of the primary chal- fragmentation. a relatively easy-to-use GC-MS
Building on the existing rep- samples through the use of lenges in metabolomics is to ◗ The Orbitrap HRAM system that provides high qual-
utation and success of the HRAM technology,” said Fausto identify significant metabolites Metabolomics Library for elec- ity data for compound discovery,
Thermo Scientific Q Exactive Pigozzo, Director of Marketing, during non-targeted studies. tron ionization (EI), metabolite identification and quantitation
GC Orbitrap and the Exactive GC GC-MS, Thermo Fisher. The addition of the new Orbitrap identification is efficiently for comprehensive analyses. The
GC Orbitrap, enhancements in- “Our R&D teams are dedicated GC-MS HRAM Metabolomics streamlined. The library in- Exactive GC Orbitrap GC deliv-
clude the addition of Variable to advancing this technology Library is helping us move in the cludes more than 800 metabo- ers sensitive, routine grade per-
electron Voltage (VeV) technol- and with these newest capabili- right direction with respect to lites and the spectra is refined formance in both targeted and
ogy, the Orbitrap GC-MS HRAM ties offer systems that continue obtaining putative metabolite and curated with the elemental non-targeted screening proto-
Metabolomics Library and the to provide customers with infor- identifications quickly, and as composition of each EI fragment cols. Both systems provide excel-
TraceFinder Automated Com- mation rich analysis.” such, allowing a fast route to be- verified. lent resolving power, mass accu-
pound Identification. These new gin the work of understanding ◗ New TraceFinder software fea- racy, linear dynamic range and
capabilities are designed to pro- “Orbitrap GC-MS technology the biological meaning of our ob- tures a specialised spectral de- sensitivity of leading Orbitrap
vide highly sensitive, selective provides a remarkable opportu- servations.” convolution library and auto- technology.
and accurate compound identi- nity to explore the metabolome, The new capabilities included mated compound identification
fication of complex samples for and alongside other technology on the Q Exactive GC Orbitrap EP News Bureau

122 EXPRESS PHARMA

December 1-15, 2017

CPhI & P-MEC INDIA 2017 SPECIAL

Industrial filtration equipment to improve
production and product quality of emulsions

Installation of Russell Finex's high-performance self-cleaning filters double the production of
water-based emulsion for Visen

VISEN IS widely known as one using a simple filter cloth sys- placement costs. Manufacturing Manager, Visen's elements and therefore min-
of the top producers of water- tem, which would catch any con- Whilst they recognised its plant in India. Following the suc- imises the possibility of skins
based emulsion. With its prod- tamination in the paint as it is cess of the trials, Visen recog- forming in the latex emulsion,
ucts being sold to numerous fed into the packing containers. importance they also acknowl- nised the potential savings that which would subsequently form
long-established paint manufac- edged the inefficiencies of this would be gained prompting blockages.
turers across the world, and Although fit for purpose, im- existing system. In search for a them to purchase ten Self-Clean-
with manufacturing facilities in provements were identified, new filtration system, Visen at- ing Russell Eco Filters. In addition, with the installa-
several locations across India, which if implemented would tended the Middle East Coatings tion of the Russell Filter Man-
Visen produces over 120,000 provide significant increases in Show in Dubai to talk to poten- The installation of the indus- agement System which is de-
metric tonne of latex emulsion production efficiency. Being an tial suppliers. Intrigued by the trial self-cleaning filtration sys- signed to continuously monitor
every year. open system meant the cloths filtration system on display at tem has enabled Visen to elimi- the filtration process, the filter is
and paint were exposed to at- the Russell Finex stand, Visen nate the problems associated able to run efficiently without
In 2011, to meet increased mospheric influences which in- approached stand representa- with the previous system. With operator involvement. This not
customer demand, Visen in- creased the possibility of skins tives to learn more about the its reusable filter element, the only safeguards operators from
vested in new manufacturing fa- forming in the latex emulsion. machine. With an in-depth con- Self-Cleaning Russell Eco Filters excessive exposure to the latex
cilities. Built in India, it was an- This could cause the industrial sultation provided, an onsite have minimised production emulsion, but also releases the
ticipated that the new plant filtration equipment to block or trial was arranged for the Self downtime as stoppages to operators to perform other tasks
would virtually double their pro- end up contaminating the final Cleaning Russell Eco Filter. change filter cloths are no longer around the factory.
duction capacity to 220,000 met- product. As a result, machine required. Substantial cost sav-
ric tonnes per year. To ensure operators were required to con- With the filter installed into ings have also been gained as the Salunkhe states, "Compared
the new plant was equipped with tinually watch the line, which in- their own production line, the removable element can be easily to our previous manual filtration
the latest technologies, the com- creased their exposure to the la- trial enabled Visen to undertake cleaned and used repeatedly, re- system, the enclosed Eco Filters
pany undertook a review of all tex emulsion. In addition, the personal monitoring of the ma- moving the high disposal and re- have allowed us to achieve good
their existing processes. filter cloths needed to be chine's effectiveness. "It was im- placement costs, which Visen housekeeping and reduce labour
changed between each new portant for us to be able to trial experienced with the filter cloth costs."
As a result of the review, it batch, and with several filling the filter at our plant prior to system.
was identified that the existing lines in operation, up to ten filter purchase, not only to ensure that The installation of the Russell
quality control procedure in cloths could be used in any one product quality would not be A key requirement was for Eco Filters has improved Visen's
place for check-screening the la- day. As the cloths were not compromised, but also to ensure the new system to operate with- manufacturing efficiencies
tex emulsion prior to packing reusable, the company also in- operators would be safeguarded out constant supervision. Being a whilst also enhancing their al-
needed to be improved. The cur- curred high disposal and re- from the potentially harmful fully enclosed system, the prod- ready meticulous quality control
rent procedure was carried out fumes," states VM Salunkhe, uct is unaffected by atmospheric procedures.

EP News Bureau

Pall Corporation partners with BioFactory Competence Center

Launches practical continuous bioprocessing courses featuring pall Life Sciences’Cadence Technologies

PALL CORPORATION, a Registration for standard ses- Marison, CEO and co-founder, scale technologies, including stream Processing, Pall Corpo-
global leader in filtration, pu- sions will be available through BCC. “As industry interest the Cadence Acoustic Separa- ration. “These unique training
rification and separation has the BCC beginning in Decem- grows in the advantages of con- tor for continuous clarification courses have been designed
partnered with the BioFactory ber and custom sessions are tinuous bioprocessing, we felt it and separation, the Cadence around real-life situations, with
Competence Center (BCC) in available upon request. necessary to introduce spe- BioSMB PD system for multi- hands-on access to enabling
Fribourg, Switzerland to cialised training for success- column chromatography, and technologies, and we are proud
launch new training courses in “The BCC launched in Jan- fully navigating this next-gen- the Cadence Inline Concentra- to support them.”
early 2018 focussed on continu- uary 2016 to deliver theoretical eration of drug making.” tor for continuous concentra-
ous bioprocessing advances. and practical biopharmaceuti- tion at various process steps. In addition to the new
The courses will detail the state cal industry training on every- The upcoming courses will courses, plans exist to build a
of the industry and the advan- thing from basic aseptic tech- highlight key advantages of in- “As drug manufacturers dedicated continuous biopro-
tages and practical implica- niques to more detailed tegrated continuous biopro- look to shift from batch to con- cessing facility in Fribourg for
tions of transitioning from applications focussed training cessing, and how best to lever- tinuous processing for both education on, and application
batch to semi- or fully-continu- from upstream to downstream age semi- or fully- continuous small and large molecule drugs, of continuous bioprocessing
ous bioprocess methodologies. processing, covering cell cul- manufacturing technologies information-sharing and con- technologies. The facility will
Pall Life Sciences’ Cadence ture, cell separation, chro- based on current resources tinued education have become also feature Pall Cadence plat-
platform technologies will be matography and concentration, and future goals. The practical key drivers of advancement,” form technologies.
featured for hands-on training. comparing single-use vs. tradi- sessions will feature Pall Life said Peter Levison, Senior
tional approaches,” stated Ian Sciences’ process development Marketing Director of Down- EP News Bureau

To subscribe: [email protected] EXPRESS PHARMA 123

December 1-15, 2017

CPhI & P-MEC INDIA 2017 SPECIAL

Werum ITSolutions and Chinese-based
Neotrident in partnership

Customers benefit from additional resources during PAS-X MES implementation

WERUM IT Solutions further configuration, installation, Level 3 systems,” says Olivier management has been working efficiently and in high quality.”
expands its PAS-X Service training and the integration of Néron, Senior VP China Opera- with foreign companies for “PAS-X Endorsed Service
Partner network. The world’s automation and equipment. tions at Werum IT Solutions. decades which enables them to
leading supplier of manufac- “Neotrident has an excellent overcome cultural differences. Partners” meet all require-
turing execution systems “We selected Neotrident reputation in China and suc- Therefore, Neotrident will pro- ments of Werum’s PAS-X Ser-
(MES) signed a partnership among many candidates based cessfully managed a wide range vide our pharma and biotech vice Partner Program. The
agreement with Neotrident. on long-time experience in the of services from single site customers with high-quality main objective is to offer the
Based in Beijing with several life sciences industry and be- projects up to large roll-outs. services and support for the same quality and competence
local offices in China, Neotri- cause of their complementary Furthermore, the Neotrident years to come.” of services to Werum cus-
dent is a leading IT solutions capabilities in terms of ISA- tomers all over the world –
provider to the Chinese life sci- Lingxiao Cao, CEO, Neotri- through reliable, experienced
ences industry. dent, “Neotrident’s long expe- and certified partners. The
rience in offering IT solutions Service Partners need to have
As a certified 'PAS-X En- to the pharma market makes comprehensive PAS-X knowl-
dorsed Service Partner Local', us a stable and reliable partner edge, participate at PAS-X
Neotrident will support Werum for Werum and its customers trainings on a regular basis,
customers in the People’s Re- during the implementation of possess experience in the reg-
public of China during the on- PAS-X MES. With our deep un- ulated industry and use a qual-
site implementation of derstanding of the daily opera- ity management system. The
Werum’s PAS-X MES. For in- tions in the industry we can certification has to be renewed
stance, Neotrident will provide perform the transition from a on a regular basis.
resources for project manage- paper-based to a digital-based
ment, MBR design, system quality control system more EP News Bureau

Aptar Pharma receives Excellence in Pharma: Sustainability
Initiative of theYear award at CPhI Worldwide 2017

The company was awarded for its Landfill Free Certification programme

APTARGROUP, A leading per cent reuse and/or recycling duction, cost savings and em- customer satisfaction surveys sion and corporate social re-
global supplier of a broad range threshold are eligible to re- ployee engagement. The pro- demonstrated the growing im- sponsibility.
of innovative dispensing and ceive internal Landfill Free gramme is incorporated as a portance of sustainability to
sealing solutions for the beauty, Certification. With more than measurable aspect of Aptar‘s customers and supply part- Yann Ghafourzadeh, VP,
personal care, home care, pre- 40 per cent of Aptar’s manu- global sustainability strategy ners. Therefore, Aptar’s inter- Sales & Operations Europe -
scription drug, consumer facturing sites already certi- and Aptar anticipates more fa- nal programme further rein- Prescription Division, Aptar
healthcare, injectables, food fied through this programme, cilities will achieve certifica- forces that Aptar is prioritising Pharma comments, “We are
and beverage markets, was Aptar has achieved significant tion in years to come. the needs of its customers in delighted to have been awarded
awarded the inaugural Excel- accomplishments in waste re- line with its own company mis- the Sustainability Initiative of
lence in Pharma: Sustainability Data from Aptar’s recent the Year at the CPhI Pharma
Initiative of the Year at CPhI Awards. It is great to be recog-
Worldwide 2017. The award nised for the progression of Ap-
was presented as part of the tar’s Landfill Free Certification
CPhI Pharma Awards Gala, programme, which has been
which took place in Frankfurt, significant within our global
Germany. sustainability strategy. We
have aligned our programme
Aptar was awarded the Ex- with our customers‘ require-
cellence in Pharma: Sustain- ments and we are dedicated to
ability Award for its Landfill responding to what sustainabil-
Free Certification programme, ity considerations are impor-
a global internal certification tant to them. We look forward
programme which promotes to further Aptar facilities ob-
the efficiencies and conserva- taining the internal Landfill
tion of natural resources in a Free Certification in the fu-
manufacturing setting. Facili- ture.”
ties that achieve at least a 90
EP News Bureau

124 EXPRESS PHARMA

December 1-15, 2017

CPhI & P-MEC INDIA 2017 SPECIAL

EKF Diagnostics’ProcalcitoninAssay gets FDAclearance

User defined application available on Beckman AU clinical chemistry analysers for LiquiColor
Procalcitonin (PCT) assay enabling quick and effective sepsis identification

EKF DIAGNOSTICS, the increases the breadth of appli- no reagent preparation and is analyser for up to four weeks. ministration of antimicrobial
global in vitro diagnostics com- cation of the LiquiColor PCT designed to be used on open PCT is a quick and effective therapy. It is an important test,
pany, announced that its Stan- assay. chemistry systems. It is avail- as the Surviving Sepsis Cam-
bio Chemistry Procalcitonin able in a liquid-stable format, adjunct marker in sepsis diag- paign (SSC) estimates that the
(PCT) LiquiColor assay has Trevor McCarthy, Sales meaning that it can remain on- nosis which helps to differenti- incidence of sepsis is 3 per
been FDA cleared and vali- Manager, EKF Central Labora- board a clinical chemistry ate between viral and bacterial 1,000 worldwide. There has
dated for use on Beckman AU tory Products, EMEA/APAC infections, so enabling early ad- been a steady rise in the num-
480, 680 and 5800 clinical said, “The news regarding the ber of patients with sepsis;
chemistry analysers. EKF is FDA clearance and Beckman globally there are now over 18
pleased to confirm the immedi- AU analyser validated applica- million cases per year.
ate availability of a user defined tion for the PCT LiquiColor as-
application (UDA) for running say will bolster trust in the In addition to improving
this 10 minute test for bacterial quality and reliability of our sepsis survival rates and im-
infection and sepsis on these product. Having EKF’s PCT as- proving antibiotic stewardship,
Beckman AU analysers. say validated on Beckman AU studies have also shown that
chemistry analysers allows us PCT testing reduces hospital
PCT is a widely accepted to provide a competitive alter- costs and length of stay. For ex-
marker for use in conjunction native product for hospital labs ample, a recent large cohort
with other tests to quickly iden- and should open up new mar- study examined whether PCT
tify sepsis and monitor pro- kets and opportunities for us to testing helps to more effec-
gression/severity over time. support improved and early de- tively manage sepsis care. The
EKF’s PCT test is designed to tection of sepsis.” study found that use of PCT
be used on an open channel of testing on day one of admission
most main brand clinical chem- The cost-effective, immuno- into the ICU lead to an average
istry analysers, including turbidimetric assay, which fea- of 1.2 fewer hospital days than
Roche Cobas, Abbott Architect tures the use of monoclonal an- patients who were not
and Hitachi systems. There- tibodies coated to latex screened and saved an average
fore, the availability of the User particles, can determine PCT of $2,759 on their total hospital
Defined Application (UDA) on from just 20µL of serum and costs.
Beckman AU analysers further plasma specimens. Conve-
niently, the reagent set requires EP News Bureau

Almirall opts for Werum’s PAS-X MES PAS-X will be imple-
mented out of the box and ac-
Rollout in German plant in Reinbek near Hamburg cording to Werum’s unique
implementation method
IN THE context of a tender- 'Ready', 'Fit', 'Build' and
ing process, the Spanish 'Run'. The benefit for Almi-
pharmaceutical company rall: short project term and
Almirall opted for Werum’s significant cost efficiency.
PAS-X Manufacturing Execu-
tion System to be installed in “We are already thrilled
the German plant in Reinbek about the Fit Phase,” says
near Hamburg. Almirall is the Maik Weber, Head of Produc-
market leader for skin medi- tion, Almirall. “Together with
cine in Germany and e.g. pro- the Werum consultants, we
duces the Balneum skin care matched our business
products. processes in the Reinbek pro-
duction site with the best-
PAS-X will be rolled out as practice-based PAS-X work-
a full-scope MES for the en- flows. Both the approach and
tire manufacturing process – the expertise of the consult-
including weighing, mass pro- ants and the results of
duction and packaging. It will this phase were really
replace the legacy production convincing.”
management system. The
new review and release work- EP News Bureau
flows will lead to more effec-
tive processes as well as com- EXPRESS PHARMA 125
pliance with regulatory
requirements. December 1-15, 2017

To subscribe: [email protected]

CPhI & P-MEC INDIA 2017 SPECIAL

Aptar Pharma to showcase products at CPHI India,Mumbai

The company will present a pharma talk focussed on connected healthcare solutions, one such
growing megatrend

APTAR PHARMA, a leading Mumbai, from November 28 – Sai Shankar Presented by Sai Shankar, sign approach, Aptar Pharma
drug delivery systems 30, 2017 Director Business Develop- supports Pharma companies
provider, will showcase Aptar ment - Connected Devices, worldwide with custom-made
Pharma’s wide product portfo- A dedicated innovation Aptar Pharma’s Exhibitor solutions, including connected
lio covering various routes of area will feature the mega- Showcase will reveal the find- technologies, for the treat-
administration, including con- trends that are currently influ- ings of a recent study on its in- ment of respiratory diseases
nected device systems for bet- encing the drug delivery in- tegrated connected pMDI. He including asthma and COPD.
ter patient adherence and dustry. will also present the com-
compliance. The products will pany’s connected health Sai Shankar’s Exhibitor
be displayed at CPhI India Further to exhibiting at devices portfolio that supports Showcase will take place on
2017 stand No H77, Hall 1, CPhI India, Aptar Pharma will respiratory treatment for November 28 from 13:00 –
which will be held at the Bom- present a pharma talk fo- patients. 13.45 at Hall 7A, Goregaon.
bay Exhibition Centre (BEC), cussed on connected health-
care solutions, one such grow- Using a patient-centric de- EP News Bureau
ing megatrend.

126 EXPRESS PHARMA

December 1-15, 2017

BUSINESS AVENUES EXPRESS PHARMA

EXPRESS PHARMA December 1-15, 2017 127

BUSINESS AVENUES EXPRESS PHARMA

128 December 1-15, 2017 EXPRESS PHARMA

BUSINESS AVENUES EXPRESS PHARMA

EXPRESS PHARMA December 1-15, 2017 129

BUSINESS AVENUES EXPRESS PHARMA

Excellence far beyond An ISO 9001 : 2015 Certified Company

TURNKEY CLEANROOM SOLUTIONS

CLEANROOM PANELS CLEANROOM HVAC

Static Pass box Dynamic Pass box Sampling Booth Horizontal LAF

Laminar Air Flow Bio-Safety Cabinet Air Showers Mobile LAF

CLEANROOM DOORS CLEANROOM EQUIPMENT

108,Swastik Regalia, Waghbil, Off Ghodbunder Road, Thane West, Mumbai

+91-22-2597 1641 / 42 +91-809 777 9747 / 992 032 4980 [email protected] www.pharmintech.net

130 December 1-15, 2017 EXPRESS PHARMA

BUSINESS AVENUES EXPRESS PHARMA

EXPRESS PHARMA December 1-15, 2017 131

BUSINESS AVENUES EXPRESS PHARMA

132 December 1-15, 2017 EXPRESS PHARMA

BUSINESS AVENUES EXPRESS PHARMA

EXPRESS PHARMA December 1-15, 2017 133

BUSINESS AVENUES EXPRESS PHARMA

134 December 1-15, 2017 EXPRESS PHARMA

BUSINESS AVENUES EXPRESS PHARMA

EXPRESS PHARMA December 1-15, 2017 135

BUSINESS AVENUES EXPRESS PHARMA

136 December 1-15, 2017 EXPRESS PHARMA

BUSINESS AVENUES EXPRESS PHARMA

Stockists & Marketing 600PRODUCTS
Professionals

Nursing Homes, Private Hospitals,
Big Multi-Specialities Hospitals,

Polyclinics, Institutions,
Trauma Centers and Doctors.

Highlights

Manufacturing of all Products in our own state
of art Plants
Manufacturing of injectables (Beta Lactam and
non Beta lactam), Tablets, Capsules, Ointment,
Lotion, Liquid orals, Eye/Ear Drops etc.
Very Competitive Price with high margin of profit
Stock Available round with Clock-timely
service & on time suppliers
Elegant Packing with unmatched Quality.
Long lasting Relationship, Committed Dealings

Inquiries for stockistship and superstockistship are solicited.
Experienced Pharma Personnels can also contact for excellent opportunity.

Export and 3rd Party inquiries are solicited.

Business opportunity OUR MARKETING DIVISIONS

For Dynamic Enthusiastic and AGROGEM
Energetic marketing Professionals
AGROVISION CARDIRON
Agron Vet Care
CARDIRON

YCHORON

PS

Wholesale Chemists AGRON OTC D DERMARON

AGRON OTC DERMARON

AGRON AYURVEDA

AGRON AYURVEDA

AGRON REMEDIES PVT LTD. CONTACT US:

Sarverkhera, Moradabad Road, Email:- [email protected]
Phone No. : 09358650929, 09359489829,
Kashipur-244713 (Uttarakhand) 08859001367, 05947275279
FAX:- 05947274929
website: agronremedies.com

EXPRESS PHARMA December 1-15, 2017 137

BUSINESS AVENUES EXPRESS PHARMA

US $4 Billion Leading Nirtogen Plant
well diversified Group manufacturer for more than 30 years

Turnkey supplies to Pharma Sector and other
industrial segments such as Chemical,
Power, Metallurgical and
Food - where we have sustained
majority market share consistently and
established ourselves as market leaders and
amongst the largest and best-of-breed air
and gas treatment systems company around
the world.

138 December 1-15, 2017 EXPRESS PHARMA

BUSINESS AVENUES EXPRESS PHARMA

EXPRESS PHARMA December 1-15, 2017 139

BUSINESS AVENUES EXPRESS PHARMA

140 December 1-15, 2017 EXPRESS PHARMA

BUSINESS AVENUES EXPRESS PHARMA

EXPRESS PHARMA December 1-15, 2017 141

BUSINESS AVENUES EXPRESS PHARMA

142 December 1-15, 2017 EXPRESS PHARMA

BUSINESS AVENUES EXPRESS PHARMA

EXPRESS PHARMA December 1-15, 2017 143

BUSINESS AVENUES EXPRESS PHARMA

ADVANTAGES OF

PRE-PREPARED TROLLEY System

over BUCKET TROLLEY System

Today´s Cleaning

Innovative Pre-prepared

3 No Heavy buckets
3 No Cross-contamination
3 > 50% less consumption of

water and chemicals
3 High on ergonomics
3 Sustainable
3 Microfiber technologie
3 Small footprint of trolley´s

The pre-prepared method is exactly what it says – every mop and cloth required for that days’ cleaning is prepared in
advance with the correct amount of water and customers validated disinfectant.

another pre-prepared mop is placed on the frame for use in the next room/area/surface. The used mop is then placed into a

B902 / 903 / 904, O2 Galleria, Minerava Industrial Estate, Mulund (West), Mumbai - 400 080
Tel : +912261716666 l Cell : +91-8976610332
Website: www.vileda-professional.com l Email: [email protected]

144 December 1-15, 2017 EXPRESS PHARMA

BUSINESS AVENUES EXPRESS PHARMA

REAL-TIME CONTROL

In-process solutions for particle size analysis

Micron and Sub-Micron Particle Sizer suitable for dry
powders, emulsions, suspensions and slurries.

INSITEC PARTICLE SIZE ANALYZER

• Size range: 0.1 – 2500μm • Intrinsic Safety to Class I, • ARTMiS Automated Real-
• URS / FAT / SAT supported Div 1 (Zone 0) Time Milling System-
• 21CFR part11 compliant Continuous Particle Size
• SOP Configurable and • Plant communication Control in RealTime
integration (OPC, Modbus,
Customizable Profibus, Discrete I/O)

P-MEC 2017

Hall No. 5 Date : 28–30 Venue : BC&EC,

Stall No. N18 November, 2017 Goregaon, Mumbai

EXPRESS PHARMA December 1-15, 2017 145

BUSINESS AVENUES EXPRESS PHARMA

WE ARE CERTIFIED FOR ISO 15378:2011,
WHICH INCLUDES BOTH ISO 9001 AND GMP

PACKAGING PRODUCTS

FOR HEALTH CARE

RUBBER DISCS & PLU NGER TABLET &
FOR DENTAL CARTRI DGES GEL APPLICATOR

RUBBER S TOPPERS DROPPER ASSE MBLY

EYE / EAR DROP BOTTLES 30ML, 60 ML & 100ML DRY S YRUP
(CONTROLLED DROP S YSTEM) BOTTLE WITH CAP & MEASURING CUP

RUBBER DISCS WITH EUROHEAD DIAGNOSTIC PACKAGING
CAPS AND FLASH BLUB

DIFFERENT SIZE CAPS DOSING S YRINGE
WITH ADAPTOR

PLASTIC MEASURING CUPS/SPOONS SYRUP SPOON SCOOPS
(for LIQUIDS & Dry Powders)/ PLASTIC CAPS (ROPP)

RUBBER WADS BEAK TYPE DROPPER, LIDS F OR TIN FEEDING BVoHiosAthiLtLNNuoo:sI:-650
OPVD DROPPER & BUILT IN DROPPER CONTAINERS SPOON
BECMG@uomrebgaaion,

BHARAT RUBBER WORKS PVT LTD.

B-46, Girikunj Industrial Estate, Off. Mahakali Caves Road,
Andheri (East), Mumbai - 400 093. INDIA.
Tel.: +91-22-2687 5361 - 64  Fax: +91-22-2687 5221 / 22
Email: [email protected]  Website: www.bharatrubberworks.com

146 December 1-15, 2017 EXPRESS PHARMA

BUSINESS AVENUES EXPRESS PHARMA

R Your Partner in HealthcareR

STERILIZING & DEPYROGENATION TUNNELS
SUITABLE FOR AMPOULES / VIALS / CARTRIDGES

MAIL US YOUR REQUIREMENTS : Venera Biotech Systems Pvt. Ltd.
[email protected]
[email protected] D - 2 / 1, RHODIA COMPOUND, AMP GATE ROAD, MIDC INDUSTRIAL AREA,
AMBERNATH (W), DIST. - THANE, MAHARASHTRA - 421501. INDIA.
EXPRESS PHARMA VOICE CONTACT : 0251 - 6946900.

December 1-15, 2017 147

BUSINESS AVENUES EXPRESS PHARMA

For almost 40 years, Domino has been a leading global producer of
innovative printing, coding and marking solutions for the Pharmaceutical
and healthcare industries.This equates to extensive experience in
serialization support.
Our technology enables manufacturers and CMO’s to comply with the
validation requirements of Good Manufacturing Practice (GMP) and
emerging global legislative standards, such as the DQSA, helping to
secure the supply chain from Product to Pallet.

Trust the experts.

Contact Domino to discuss your serialization

Domino Printech India LLP
Corporate office- Plot No. 167, HSIDC, Udyog Vihar, Phase I, Gurgaon-
122016, Haryana, India
Tel: +91 124 488 6100, [email protected]

148 December 1-15, 2017 EXPRESS PHARMA

BUSINESS AVENUES EXPRESS PHARMA

28-30 Nov 2017, BEC, Mumbai December 1-15, 2017 149
Visit us : Booth No.: R36, Hall No.: 7A

EXPRESS PHARMA

BUSINESS AVENUES EXPRESS PHARMA

VISIT US @

HALL #5, STALL #N‐36 07TH ‐ 12TH FEB, 2018 Multiple Products Under One Roof
28TH ‐ 30TH NOV, 2017
GANDHINAGAR, AHMEDABAD, GUJARAT. INDIA for Food & Bio-Pharma Industries
BOMBAY EXHIBITION CENTER, MUMBAI, INDIA.
We are specialized in manufacturing Platinum Cured Silicone Tubes,
Braided Hoses, Inflatable Seals / Gaskets and customized polymer
solution for food, medical and pharmaceutical industries application.

Imavac™ - Silicone Hose Imawrap® - Silicone Hose Imaprene™ - Thermoplastic Imavacfit® - Silicone hose Silicone Inflatable Seals
reinforced with Polyester Braiding & Gaskets
reinforced with SS 316 helical wire reinforced with Polyester Fabric Elastomer Tube (TPE)
and SS 316 helical wire
& SS 316 helical wire
www.amipolymer.com
TM

Ami Polymer Pvt. Ltd.

“Sealing Expert in Silicone” [email protected]

An ISO 9001:2008/14001:2004/18001:2007 & Clean Room
Certified Co. DMF #26201 accredited by USFDA

150 December 1-15, 2017 EXPRESS PHARMA

BUSINESS AVENUES EXPRESS PHARMA

EXPRESS PHARMA December 1-15, 2017 151

BUSINESS AVENUES EXPRESS PHARMA

Balsam Ultimate Solution Balsam Balsam Ultimate Solution
For Your Requirement of
Balsam For Your Requirement of Life sciences & Technologies
Healthcare Consultants Pharma Machinery
Life sciences & Technologies API & Intermediate &

Healthcare Consultants Equipment

Our services include API manufacturing under strict cGMP
product release & process validation. All are delivered as per
European, US & Japanese standards.

LYMECYCLINE Fluid Bed Processor Fluid Bed Dryer

Active Pharmaceutical Ingredients Rapid Mixer Granulator

Coating Pan Liquid Syrup Manufacturing

Balsam Life Sciences and Technologies Pvt. Limited. Balsam Life Sciences and Technologies Pvt. Limited.

C/O Indcon Corporation, Bharti Industries, Opp: State Bank of India,Vicco Naka, C/O Indcon Corporation, Bharti Industries, Opp: State Bank of India,Vicco Naka,
Off Kalyan Shil Road, MIDC Phase I Dombivali (East) Off Kalyan Shil Road, MIDC Phase I Dombivali (East)
Thane - 421201 Maharashtra India Thane - 421201 Maharashtra India

+91 251 6516564 +91 9920104145 / 9967975365 / 9920745365 / 99222260666 +91 251 6516564 +91 9920104145 / 9967975365 / 9920745365 / 99222260666
[email protected] www.balsamlifesciences.com [email protected] www.balsamlifesciences.com
Skype - balsamlifesciences Skype - balsamlifesciences

Cold Chamber EXPRESS PHARMA

Various size & capacity of chambers available on request.
152 December 1-15, 2017

BUSINESS AVENUES EXPRESS PHARMA

EXPRESS PHARMA December 1-15, 2017 153

BUSINESS AVENUES EXPRESS PHARMA

Guaranteed safety & reliability
of your life saving products.

WFI Stills and Pure Steam Generators

Machinfabrik Industries Pvt. Ltd. R - 89 / 90, Rabale, MIDC., Thane Belapur Road, Navi Mumbai - 400701, India
www.machinfabrik.com | [email protected] | 91-22-6736 8200

154 December 1-15, 2017 EXPRESS PHARMA

BUSINESS AVENUES EXPRESS PHARMA

EXPRESS PHARMA December 1-15, 2017 155

BUSINESS AVENUES EXPRESS PHARMA

With high performance comes design freedom.
A choice of 9 RAL colors to go with your brand image.

You demand. We fulfill. 9 RAL colors available

Bangalore I Delhi I Guwahati I Hyderabad I Jammu I Kolkata I
Mumbai I Vadodara I [email protected] I www.labguard.biz
Call National Hotline - 022 65650606
The Reagent Racks featuring in this image is not a standard LabGuard product.

TM

S. P. PRODUCTS
PHARMA EQUIPMENTS AT IT'S BEST

S.S. MULTIPURPOSE S.S. VIAL / AMPOULE BOX S.S. CAGE TROLLEY S.S. TROLLEY FOR STD S.S. CONTAINER S.S. STEP OVER BENCH S.S. KEY BOX S.S. SIEVES S.S. TRAY S.S. SPOON /
TROLLEY WEIGHT / STORAGE (5LTR - 500LTR) WITH SHOE RACK TROLLEY MEASURING JAR / SCOOPS

S.S. STERILLIUM STAND

S.S. HELMET STAND S.S. CHEMIST TABLE. S.S. STERILE CABINET S.S. SIEVES FOR SIFTER / S.S. CROSS OVER BENCH SS INPROCESS S.S. TROLLEY FOR S.S. CABINET FOR S.S. STREET SHOE RACK
WITH UV LIGHT MULTIMILL / CADMILL 'L TYPE & 'C TYPE CONTAINER HAND DISINFECTANT / FBD BAGS STORAGE
HAND GLOVES / MASK /ROLLER

S.S. STEP S.S. PERFORATED / S.S. PASS BOX S.S. DRAIN TRAP TM S.S. PALLET S.S. ANTIVIBRATION TABLE
LADDER PLAIN TABLE (SINGLE / DOUBLE SEAL)
S.S. PADDLE / TILTING DUSTBIN TM

S.S. FIX /
REV STOOL / CHAIR

Contact: S.S. DIES & PUNCHES CABINET

S.S. LOCKER S.S. CABINET FOR BLISTER S.S. II CHANGE Mr. Kiran Shah / Mr. Chirag Shah

FOR KEEPING CHANGE PART / STRIP CH PART / S.S. VISITOR S.S. CABINET FOR S.S. WRITING DESK CROSS OVER BENCH
APPRON CABINET MULTIMILL SIEVES WITH DRAWERS
STREET GARMENT POLYBAG

• All products are custom OFFICE: F-823, VEENA SANTOOR BLDG., NEAR PAWANDHAM, BEHIND 'D' MART, MAHAVIR NAGAR EXTN. ROAD, BORIVALI (W),
made & available in 304, 316 & 316L Quality MUMBAI-400092. TELEFAX: 28197068 / 3082 MOBILE: 98200 54453. Email: [email protected] URL: www.pharmaequipments.com
with optional Matt & Mirror finish.

• We undertake the side work of Cladding WORKS: W6, OM SAI COMMERCIAL COMPLEX, GODDEO ROAD, NEAR EKVIRA GAS GODOWN, BHAYENDER (EAST), THANE - 401 105 TEL: 2819 3082
of Machinery & others.

156 December 1-15, 2017 EXPRESS PHARMA

BUSINESS AVENUES EXPRESS PHARMA

“TECHNOPTIONS”group … emerging .. beyond technology ...

PHARMACEUTICAL METAL DETECTION MOISTURE & Bulk DENSITY / WEIGHT
SYSTEM Measuring - Monitoring - Control

for .. TABLET / CAPLETS / SOFT and HARD (Hand-Held / Laboratory / At-Line / In-Process)
GELATIN CAPSULES / POWDER / GRANULES
RECORD & CONTROL the
etc. “Product Moisture” during

FLUID BED DRYER

process …
ON-LINE .. REAL-TIME

PHARMA TECHNOLOGY Visit us at:

PHARMA FLEX 28-30 November 2017
HALL 5 / STALL N1
::COMBI::
DEDUSTER Exclusive Representation in INDIA:
METAL DETECTOR
PRODUCT DISTRIBUTION

PHARMA Series – WIP & WOL Series

Containment levels:

- “DT” Dust Tight Series <OEB3
- “C” Containment Series ≤OEB3
- “HC” HIGH Containment Series

≤OEB-5
SS 316
SPIRAL

MODULAR
Segment
SPIRAL

EXPRESS PHARMA December 1-15, 2017 157

BUSINESS AVENUES EXPRESS PHARMA

158 December 1-15, 2017 EXPRESS PHARMA

BUSINESS AVENUES EXPRESS PHARMA

LABORATORY EQUIPMENTS

G Walk in stability Chamber/Cold Room
G -86 0C Ultra-low Temperature Freezer
G Humidity Chamber/Stability Chamber
G Cooling Incubator
G Bench Top and Refrigerated Centrifuge
G Deep Freezer/Laboratory Refrigerator
G Cold Cabinet
G Orbital Shaking Incubator
G Rotary Shaker
G Laboratory/Magnetic Stirrer
G Vortex Mixer
G Healthcare Equipments

Walk in Chamber

Roller Tube Mixer Micro Mini Centrifuge

Dry Hot Air Oven

Magnetic Stirrers Microplate Shaker Single Door Refrigerator Upright Freezer

Magnetic Multi Vortexer
Coupling
Laboratory Centrifuges

Laboratory Stirrers

Bench Top Orbital Shaking Incubator Neya Centrifuges Heating Incubator Humidity Chamber Medico Plus
with TFT Display

REMI SALES & ENGINEERING LTD.

Remi House, 3rd Floor, 11, Cama Industrial Estate, Walbhat Road, Goregaon (East), Mumbai-400 063. India

Tel: +91 22 4058 9888 / 2685 1998  Fax: +91 22 4058 9890  E-mail: [email protected] Website: www.remilabworld.com

EXPRESS PHARMA December 1-15, 2017 159

BUSINESS AVENUES EXPRESS PHARMA

Silicone Rubber Profile, Gasket, Cords & Tube.
(-40 to + 220 Deg. C)

Rubber Cords Gasket, ‘O’ Ring & Sheet in NEOPRENE,
EPDM, NITRILE, VITON, FLUORO SILICONE for
Pharma, Food Chemical & Medical Industries.

Single & Multi Core Cables. (1.1 KV to 11 KV. Grade)

Welding, thermocouple, FRLS & TRS Cables.

High Temp, ResistanCe Cables (-60 to + 1200 Deg. C)

RoHS Certified

1,2 & 9, Jay Vailankanni Indl. Est., B/h, Tirupati Gas Godown, United Rubber compound, Bhayander (East), Dist. : Thane - 401 105
Phone: + 91 - 22-28147776 Mob.: 9987228484 9869804701
[email protected]

www.centurycablesindia.com / www.centuryrubbercables.net

160 December 1-15, 2017 EXPRESS PHARMA